The Karolinska Institute is working on a project to scale up the production of mesenchymal stem cells (MSCs), which can reduce inflammation and repair damaged tissue. Scientists within Cellcolabs aim to make these treatments affordable and reliable, targeting a price cut of up to 90% within the next decade. Recent advancements allow for the harvesting of billions of MSCs from single donations, providing ample doses for treatments. The CEO, Dr. Mattias Bernow, expresses strong optimism about the significant milestones approaching in the field of regenerative medicine.
Mesenchymal stem cells (MSCs) can reduce inflammation, repair damaged tissue, and modulate the immune system, with potential to treat chronic diseases and delay ageing.
Cellcolabs aims to cut prices of MSC treatments by up to 90% within the next decade, capitalizing on scientific, regulatory, and technological advances.
The latest harvest from a single donation yielded 4.1 billion MSCs, enough for up to 200 standard doses, signaling substantial production capabilities.
Dr. Mattias Bernow expresses optimism about MSCs, stating, 'I truly believe that we're at an inflection point in the history of medicine.'
Collection
[
|
...
]